NDAORALTABLET, EXTENDED RELEASE
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
JENTADUETO XR (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO XR is a fixed-dose combination oral tablet combining linagliptin (a DPP-4 inhibitor) and metformin hydrochloride in extended-release formulation, approved by the FDA on May 27, 2016. It is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. The combination works by inhibiting dipeptidyl peptidase-4 to increase incretin levels, while metformin reduces hepatic glucose production and improves insulin sensitivity. JENTADUETO XR positions itself as a convenient once-daily dual-mechanism therapy for patients requiring both agents.
$0.0BPart D
11.6 years to LOEMechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product supports roles including brand managers focused on managing a niche but stable diabetes franchise, medical science liaisons engaging endocrinologists and primary care physicians on combination therapy benefits, and specialty sales representatives. Skills relevant to this product include knowledge of type 2 diabetes treatment algorithms, familiarity with DPP-4 inhibitor clinical data, and ability to articulate advantages of extended-release formulation dosing convenience. Currently zero linked job openings are documented, reflecting the mature and stable commercial status of the product.
Company
Worked on JENTADUETO XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.